Related Experiment Video
Updated: Jun 26, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Rilmenidine: a novel antihypertensive agent
1Department of Internal Medicine, Hôpital Broussais, Paris, France.
Abstract:
Rilmenidine is a novel antihypertensive agent related to alpha 2-agonists. Pharmacologic and clinical data concerning efficacy and acceptability of rilmenidine, its effects on physiologic functions, and hypothesis of mechanism of action are described in this report. The dominant aspect of rilmenidine is the observed dissociation at therapeutic doses between antihypertensive and central effects. In this respect, several findings resulting from fundamental pharmacology, clinical pharmacology, and therapeutics differentiate rilmenidine from clonidine and related drugs. Hypotheses to explain the results observed with rilmenidine involve unknown properties that could counteract with the alpha 2-adrenoceptor-mediated sedation, respective contribution of central and peripheral components to the activity of rilmenidine, and possible contribution of imidazoline receptors.
More Related Videos
Related Concept Videos
Antihypertensive Drugs: Thiazide-Class Diuretics
Antihypertensive Drugs: Potassium-Sparing Diuretics
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Drugs: Direct Renin Inhibitors
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Hypertension IV: Drug Therapy and Lifestyle Modifications

